Across
- 4. Single oral drug in the class
- 6. High rate of secondary failure
- 7. Drug in 6 Across safer in CKD
- 8. Contraindicated in heart failure
Down
- 1. Drug in 6 Down not labeled for Heart Failure
- 2. UKPDS trial showed a reduction in ASCVD risk
- 3. Oral drug in 4 Across with complicated dosing instructions
- 5. Drug in 8 Across with dose-dependent risks (namely, edema)
- 6. Derived from the bark of apple trees
- 9. Not to be used in combination with GLP1s